Video

Study of P97 Inhibitors in Mantle Cell Lymphoma

Author(s):

Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).

Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).

P97 is an ATPase that restores protein to homeostasis in cells and promotes retrotranslocation of misfolded proteins from the endoplasmic reticulum (ER), says Rao.

Researchers are working to target MCL with new agents that can induce ER stress. And when p97 function is inhibited, ER Rao adds, the ER becomes stressed, suggesting that p97 inhibitors could be effective the treatment of MCL.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD